Critical Development Needs for Recombinant Blood-Coagulation Factors

O. B. Ustinnikova; O. B. Runova; E. V. Novikova; V. P. Bondarev; E. V. Lebedinskaya

doi:10.1007/s11094-016-1492-0

Critical Development Needs for Recombinant Blood-Coagulation Factors

Авторы: Ustinnikova O.B.¹, Runova O.B.¹, Novikova E.V.¹, Bondarev V.P.¹, Lebedinskaya E.V.¹
Учреждения:
1. State Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Public Health of the Russian Federation
Выпуск: Том 50, № 9 (2016)
Страницы: 573-576
Раздел: Molecular-Biological Problems of Drug Design and Mechanism of Drug Action
URL: https://ogarev-online.ru/0091-150X/article/view/244439
DOI: https://doi.org/10.1007/s11094-016-1492-0
ID: 244439

Цитировать

Полный текст

Открытый доступ
Доступ закрыт

Доступ предоставлен
Доступ закрыт

Только для подписчиков

Аннотация
Об авторах
Список литературы
Дополнительные файлы
Статистика

Аннотация

Critical development needs for recombinant blood-coagulation factors (RBCFs) are reviewed. The production of less immunogenic drugs with suppressed induction of inhibitory antibodies and prolonged therapeutic effects resulting from an increased inactivation threshold is demonstrated to be a major need for designing new RBCF modifications differing in structure and composition from endogenous blood-coagulation factors while retaining their activity.